Alford, C., Wilson, SJ (2008) Effects of hypnotics on sleep and quality of life in insomnia. In: Verster, JC, Pandi-Perumal, SR, Streiner, DL (eds), Sleep and Quality of Life in Medical Illness. Humana Press, pp. 49-62.
2.
Breslau, N., Roth, T., Rosenthal, L., Andreski, P. (1996) Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry39: 411-418.
3.
Brunello, N., Bettica, P., Amato, D., Maier, G., Nutt, D. (2008) Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. ECNP Congress 2008. Eur Neuropsychopharmacol 18 (Suppl. 4): S581.
4.
Chevalier, H., Los, F., Boichut, D., Bianchi, M., Nutt, DJ, Hajak, G., et al. (1999) Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol13: S21-S24.
5.
de Haas, SL, de Visser, SJ, van der Post, JP, Schoemaker, RC, van Dyck, K., Murphy, MG, et al. (2008a) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol22: 24-32.
6.
de Haas, SL, Franson, KL, Schmitt, JAJ, Cohen, AF, Fau, J-B., Dubruc, C., et al. (2008b) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A !2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol (in press).
7.
Doble, A., Martin, IL, Nutt, DJ (2004) Calming the brain: benzodiazepines and related drugs from laboratory to clinic. London: Martin Dunitz Limited.
8.
Dombrovski, AY, Mulsant, BH, Houck, PR, Mazumdar, S., Lenze, EJ, Andreescu, C., et al. (2007) Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord103: 77-82.
9.
Estivill, SE, Bove, A., Garcia-Borreguero, D., Paniagna, J., Pin, G., Puertas, FJ, et al. : Insomnia Consensus Group ( 2003) Consensus on drug treatment, definition and diagnosis for insomnia. Clin Drug Investig23: 351-385.
10.
Fava, M., Asnis, G.,, Shrivastava, R., Lydiard, RB, Bastani, B., Sheehan, D., et al. (2008) Improved insomnia symptoms and daily functioning in patients with comorbid major depressive disorder and insomnia following zolpidem extended-release 12.5 mg and escitalopram co-treatment. APSS Meeting 2008 Sleep 31 (Abstract Supplement): A324.
11.
Fava, M., McCall, WV, Krystal, A., Wessel, T., Rubens, R., Caron, J., et al. (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry59: 1052-1060.
12.
Ford, DE, Kamerow, DB (1989) Epidemiological study of sleep disturbances and psychaitric disorders: an opportunity for prevention. JAMA262: 1479-1484.
13.
Godet-Cayre, V., Pelletier-Fleury, N., Le, VM, Dinet, J., Massuel, MA, Leger, D. (2006) Insomnia and absenteeism at work. Who pays the cost. Sleep29: 179-184.
14.
Green, A., Hicks, JA, Weekes, R., Wilson, SJ (2005) A cognitive-behavioural group intervention for people with chronic insomnia: an initial evaluation. Br J Occup Ther68: 518-522.
Holt, RA, Bateson, AN, Martin, IL (1996) Chronic treatment with diazepam or abecarnil differently affects the expression of GABAA receptor subunit mRNAs in the rat cortex. Neuropharmacology35: 1457-1463.
17.
Jindal, RD, Buysse, DJ, Thase, ME (2004) Maintenance treatment of insomnia: what can we learn from the depression literature. Am J Psychiatry161: 19-24.
18.
Kopp, C., Rudolph, U., Low, K., Tobler, I. (2004) Modulation of rhythmic brain activity by diazepam: GABA(A) receptor subtype and state specificity. Proc Natl Acad Sci U S A101: 3674-3679.
19.
Krystal, AD, Walsh, JK, Laska, E., Caron, J., Amato, DA, Wessel, TC, et al. (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep26: 793- 799.
20.
Leger, D. (1994) The cost of sleep-related accidents: a report for the national commission on sleep disorders research. Sleep17: 84-93.
21.
Lingford-Hughes, A., Hume, SP, Feeney, A., Hirani, E., Osman, S., Cunningham, VJ, et al. (2002) Imaging the GABAbenzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab22: 878-889.
22.
McKernan, RM, Rosahl, TW, Reynolds, DS, Sur, C., Wafford, KA, Atack, JR, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci3: 587-592.
23.
Morin, CM, Bootzin, RR, Buysse, DJ, Edinger, JD, Espie, CA, Lichstein, KL (2006) Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004). Sleep29: 1398-1414.
24.
Neckelmann, D., Mykletun, A., Dahl, AA (2007) Chronic insomnia as a risk factor for developing anxiety and depression. Sleep30: 873- 880.
25.
Nutt, DJ (2005a) Death by tricyclic: the real antidepressant scandal . J Psychopharmacol19: 123-124.
26.
Nutt, DJ (2005b) NICE: The National Institute of Clinical Excellence - or Eccentricity? Reflections on the Z-drugs as hypnotics. J Psychopharmacol19: 125-127.
27.
Nutt, DJ (2008) presentation at the 50th CINP meeting Munich.
28.
Nutt, DJ, Malizia, AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry179: 390-396.
29.
Nutt, DJ, Taylor, SC, Little, HJ, Standing, BC, Gale, RG (1988) Changes in benzodiazepine / GABA receptor complex function in benzodiazepine tolerant mice. Psychopharmacology (Berl)95: 407- 412.
30.
Perrault, G., Morel, E., Sanger, DJ, Zivkovic, B. (1992) Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther263: 298-303.
31.
Piot, O., Betschart, J., Stutzmann, JM, Blanchard, JC (1990) Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice. Neurosci Lett117: 140-143.
32.
Pollack, M., Kinrys, G., Krystal, A., McCall, WV, Roth, T., Schaefer, K., et al. (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry65: 551-562.
33.
Roth, T., Walsh, JK, Krystal, A., Wessel, T., Roehrs, TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med6: 487-495.
34.
Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, JA, Fritschy, JM, et al. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature401: 796- 800.
35.
Sheehan, D., Asnis, G., Shrivastava, R., Lydiard, RB, Bastani, B., Roth, T., et al. (2008) Zolpidem extended-release 12.5 mg coadministered with escitalopram improves insomnia symptoms and next-day functioning in generalized anxiety disorder comorbid with chronic insomnia. APSS Meeting 2008 Sleep 31(Abstract Supplement): A325.
36.
Stewart, R., Besset, A., Bebbington, P., Brugha, T., Lindesay, J., Jenkins, R., et al. (2006) Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep29: 1391-1397.
37.
Whiting, PJ (2003) GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery. Drug Discov Today8: 445-450.
38.
Wilson, SJ, Nutt, DJ (2007) Treatment of insomnia. Psychiatry6: 301- 304.